|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000101004 |
Summary for NINL |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000101004 | Gene symbol | NINL |
| Gene name | ninein like | |
| HGNC | 29163 | |
| Entrez ID | 22981 | |
| Gene type | protein_coding | |
| Synonyms | NINL|KIAA0980|NLP | |
| UniProtAcc | Q9Y2I6 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NINL |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| NINL | 1.13e+03 | -1.31e+00 | 1.03e-01 | -1.27e+01 | 5.09e-37 | 5.82e-36 | KIRC |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for NINL |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NINL |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg09088834 | chr20:25584824 | CGI:chr20:25584801-25585604 | promoter,gene body | 3.17e-01 | 1.98e-01 | 2.68e+00 | 7.34e-03 | 2.37e-02 | 1.19e-01 |
| GBM | cg17729667 | chr20:25585746 | CGI:chr20:25584801-25585604 | promoter | 4.99e-01 | 3.92e-01 | 2.06e+00 | 3.98e-02 | 4.60e-02 | 1.07e-01 |
| ACC | cg14121845 | chr20:25585877 | CGI:chr20:25584801-25585604 | promoter | 3.52e-01 | 4.89e-01 | -2.00e+00 | 4.57e-02 | 4.79e-02 | -1.36e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| COAD | cg13727122 | chr20:25585544 | CGI:chr20:25584801-25585604 | promoter | 2.41e-01 | 1.88e-02 | 2.37e+00 | 1.77e-02 | 2.25e-02 | 2.23e-01 |
| COAD | cg12358000 | chr20:25585542 | CGI:chr20:25584801-25585604 | promoter | 2.60e-01 | 3.88e-02 | 2.26e+00 | 2.41e-02 | 2.85e-02 | 2.21e-01 |
| LIHC | cg16686733 | chr20:25585927 | CGI:chr20:25584801-25585604 | promoter | 3.75e-01 | 2.15e-01 | 2.88e+00 | 3.94e-03 | 5.35e-03 | 1.59e-01 |
| LIHC | cg17729667 | chr20:25585746 | CGI:chr20:25584801-25585604 | promoter | 3.48e-01 | 2.15e-01 | 2.69e+00 | 7.11e-03 | 9.01e-03 | 1.33e-01 |
| LIHC | cg03522245 | chr20:25585834 | CGI:chr20:25584801-25585604 | promoter | 2.80e-01 | 1.06e-01 | 3.71e+00 | 2.10e-04 | 3.98e-04 | 1.74e-01 |
| LIHC | cg14121845 | chr20:25585877 | CGI:chr20:25584801-25585604 | promoter | 4.30e-01 | 2.89e-01 | 3.40e+00 | 6.78e-04 | 1.12e-03 | 1.41e-01 |
| CHOL | cg26158279 | chr20:25585031 | CGI:chr20:25584801-25585604 | promoter,gene body | 5.43e-02 | 1.72e-01 | -3.24e+00 | 1.18e-03 | 1.07e-02 | -1.18e-01 |
| CHOL | cg09088834 | chr20:25584824 | CGI:chr20:25584801-25585604 | promoter,gene body | 2.13e-01 | 4.35e-01 | -3.54e+00 | 4.02e-04 | 8.32e-03 | -2.22e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg16686733 | chr20:25585927 | CGI:chr20:25584801-25585604 | promoter | 2.16e-01 | 8.20e-02 | 4.45e+00 | 8.73e-06 | 1.47e-05 | 1.34e-01 |
| BRCA | cg14121845 | chr20:25585877 | CGI:chr20:25584801-25585604 | promoter | 3.09e-01 | 2.03e-01 | 4.28e+00 | 1.86e-05 | 3.02e-05 | 1.07e-01 |
| HNSC | cg03522245 | chr20:25585834 | CGI:chr20:25584801-25585604 | promoter | 1.84e-01 | 7.81e-02 | 2.28e+00 | 2.23e-02 | 2.95e-02 | 1.06e-01 |
| HNSC | cg14121845 | chr20:25585877 | CGI:chr20:25584801-25585604 | promoter | 2.79e-01 | 1.44e-01 | 2.01e+00 | 4.41e-02 | 4.56e-02 | 1.35e-01 |
| COAD | cg09088834 | chr20:25584824 | CGI:chr20:25584801-25585604 | promoter,gene body | 5.12e-01 | 4.11e-01 | 2.47e+00 | 1.33e-02 | 1.94e-02 | 1.00e-01 |
| COAD | cg15001687 | chr20:25585700 | CGI:chr20:25584801-25585604 | promoter | 3.11e-01 | 9.72e-02 | 1.97e+00 | 4.94e-02 | 4.94e-02 | 2.13e-01 |
| COAD | cg17729667 | chr20:25585746 | CGI:chr20:25584801-25585604 | promoter | 3.71e-01 | 1.73e-01 | 2.30e+00 | 2.16e-02 | 2.75e-02 | 1.99e-01 |
| BLCA | cg14121845 | chr20:25585877 | CGI:chr20:25584801-25585604 | promoter | 3.76e-01 | 2.34e-01 | 1.99e+00 | 4.69e-02 | 4.77e-02 | 1.41e-01 |
Top |
Exon skipping events with PSI in TCGA for NINL |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NINL |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| LUAD | NINL-201 | chr20_25582580_- | 2.83e-01 | 5.63e-01 | -2.74e+00 | 6.17e-03 | 2.32e-02 | -2.79e-01 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NINL |
| TFs related to NINL. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | ZNF141 | NINL | 2.44e+00 | 1.79e-03 | 4.19e+00 | 9.81e-01 | Female-biased |
| GBM | GLIS2 | NINL | 4.23e+00 | 9.83e-01 | 2.97e+00 | 5.74e-03 | Male-biased |
| GBM | NR1H4 | NINL | 4.21e+00 | 9.84e-01 | 2.84e+00 | 4.03e-03 | Male-biased |
| GBM | TCF3 | NINL | 4.14e+00 | 9.81e-01 | 2.85e+00 | 5.30e-03 | Male-biased |
| GBM | ZNF141 | NINL | 4.36e+00 | 9.88e-01 | 2.89e+00 | 3.01e-03 | Male-biased |
| GBM | ZNF28 | NINL | 4.36e+00 | 9.86e-01 | 3.04e+00 | 4.94e-03 | Male-biased |
| MESO | ZNF334 | NINL | 2.00e+00 | 4.03e-04 | 4.13e+00 | 9.88e-01 | Female-biased |
| MESO | ZNF418 | NINL | 1.59e+00 | 6.60e-05 | 4.17e+00 | 9.89e-01 | Female-biased |
| MESO | ZNF79 | NINL | 2.07e+00 | 6.15e-04 | 4.10e+00 | 9.87e-01 | Female-biased |
| NINL related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NINL |
| RBPs related to ES in NINL. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| THCA | SAMD4A | exon_skip_355617 | 6.74e+00 | 9.82e-01 | 6.34e+00 | 2.39e-03 | Male-biased |
| NINL related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs6043498 | chr20:15735872:T:G | - | -0.124889077443799 | 0.0275686059918208 | PAAD | Female-baised eQTL |
| rs1535245 | chr20:19690641:G:A | - | 0.145350220632662 | 0.010016408711012 | KIRC | Female-baised eQTL |
| rs1203886 | chr20:22563877:C:T | - | 0.104806022623083 | 0.0138396116594624 | KIRC | Female-baised eQTL |
| rs2471 | chr20:22564111:T:C | - | 0.104806022623083 | 0.0138396116594624 | KIRC | Female-baised eQTL |
| rs1203876 | chr20:22560277:A:C | - | 0.103702048755412 | 0.0174350200405012 | KIRC | Female-baised eQTL |
| rs1203884 | chr20:22563062:A:G | - | 0.103702048755412 | 0.0174350200405012 | KIRC | Female-baised eQTL |
| rs1203899 | chr20:22572658:C:T | - | 0.101271868053207 | 0.0309090230223812 | KIRC | Female-baised eQTL |
| rs1203873 | chr20:22557295:T:C | - | 0.104388762947335 | 0.0399131205323101 | KIRC | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs2235586 | chr20:17524262:C:G | - | 0.300009703244878 | 7.39284284201019e-06 | READ | Male-baised eQTL |
| rs1329821 | chr20:16179783:G:A | - | 0.189711335343316 | 0.0218619664727886 | READ | Male-baised eQTL |
| rs66521063 | chr20:16180217:G:A | - | 0.188726294832443 | 0.023595001639285 | READ | Male-baised eQTL |
| rs72470563 | chr20:22580294:T:A | - | 0.11183803950537 | 0.0189685895990859 | SARC | Male-baised eQTL |
| rs6113722 | chr20:22576461:G:A | - | 0.111355920027561 | 0.0204563839366006 | SARC | Male-baised eQTL |
| rs6048168 | chr20:22533968:G:A | - | 0.109417903389788 | 0.0261575754889217 | SARC | Male-baised eQTL |
| rs12481297 | chr20:22534890:G:A | - | 0.108650895066382 | 0.0292836044433578 | SARC | Male-baised eQTL |
| rs6048202 | chr20:22571368:G:A | - | 0.103479041063427 | 0.04279241398896 | SARC | Male-baised eQTL |
| rs6048197 | chr20:22569319:G:A | - | 0.103302571933868 | 0.0430467137734158 | SARC | Male-baised eQTL |
| rs6048199 | chr20:22569807:T:C | - | 0.103302571933868 | 0.0430467137734158 | SARC | Male-baised eQTL |
| rs6036152 | chr20:22575955:A:C | - | 0.103302571933868 | 0.0430467137734158 | SARC | Male-baised eQTL |
| rs6081195 | chr20:18536424:G:T | - | -0.0515275789698755 | 0.0292104000438366 | BLCA | Male-baised eQTL |
| rs28892956 | chr20:18539888:G:A | - | -0.0515275789698755 | 0.0292104000438366 | BLCA | Male-baised eQTL |
| rs2295559 | chr20:18543383:A:G | - | -0.0515275789698755 | 0.0292104000438366 | BLCA | Male-baised eQTL |
| rs6112023 | chr20:18550377:G:T | - | -0.0509989438670256 | 0.0349238412858883 | BLCA | Male-baised eQTL |
| rs3736775 | chr20:18548589:T:A | - | -0.0510860244516203 | 0.0356782069240862 | BLCA | Male-baised eQTL |
| rs3748450 | chr20:18490020:A:G | - | -0.073491673414901 | 0.0364771817320995 | BLCA | Male-baised eQTL |
| rs911114 | chr20:18525361:A:G | - | 0.0757923101201374 | 0.041501434502092 | BLCA | Male-baised eQTL |
| rs2295556 | chr20:18532961:C:T | - | -0.049585939152552 | 0.0456113978523663 | BLCA | Male-baised eQTL |
| rs6045426 | chr20:18472020:C:T | - | -0.0713256571133579 | 0.0478836176097329 | BLCA | Male-baised eQTL |
| rs3818217 | chr20:18532095:T:G | - | -0.0488011854201872 | 0.0490161164660837 | BLCA | Male-baised eQTL |
| rs1577924 | chr20:35196485:C:G | - | 0.0515190587740879 | 0.0301247903220753 | COAD | Male-baised eQTL |
| rs8114671 | chr20:35201339:C:A | - | 0.0511954522687063 | 0.0427264225957984 | COAD | Male-baised eQTL |
| rs35193912 | chr20:35197247:C:T | - | 0.050760473670702 | 0.0432095222649603 | COAD | Male-baised eQTL |
| rs34515766 | chr20:35197418:C:G | - | 0.050760473670702 | 0.0432095222649603 | COAD | Male-baised eQTL |
| rs74786956 | chr20:35198240:T:C | - | 0.0510116279710159 | 0.0433705031217744 | COAD | Male-baised eQTL |
| rs6142322 | chr20:35200735:C:A | - | 0.0506069659445145 | 0.0474722496818408 | COAD | Male-baised eQTL |
| rs6142324 | chr20:35201240:C:T | - | 0.0509483149319861 | 0.0476645362387441 | COAD | Male-baised eQTL |
| rs4911478 | chr20:35194822:A:C | - | 0.0504891006505535 | 0.0483596445586076 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000101004 |
| CpG Site: cg13486641 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.436206414872023 | |
 | Gene ID: ENSG00000101004 |
| CpG Site: cg06913219 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: - | |
| Female Effect: -0.154459087727949 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg13486641 | chr20:25499212 | gene | -0.436206414872023 | 1.98881826251447e-22 | -0.8790688749355854 | 8.159179134472174e-27 | PAAD |
| cg06913219 | chr20:25453242 | gene,exon,UTR | -0.154459087727949 | 7.32851127172945e-06 | -0.34066493513200397 | 2.3902167225003425e-08 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NINL |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
